CAJ | 학술논문

目的评价光动力疗法联合雷珠单抗(Ranibizumab)玻璃体腔注射治疗视网膜大动脉瘤的疗效.方法对2010年1月至2014年2月在解放军第四七四医院眼科就诊的21例(21只眼)经光动力疗法(PDT)联合Ranibizumab玻璃体腔注射治疗视网膜大动脉瘤(RAM)患者资料进行回顾性分析.其中男性9例,女性12例,年龄56～80岁,平均年龄(61.5±10.6)岁,均为初次就诊或是以前就诊已确诊,但是从未接受治疗的视网膜大动脉瘤患者.所有患者在光动力疗法后72 h后至1周内行Ranibizumab玻璃体腔注射(0.5 mg/0.05 ml),并在注射后4、8、12周随访,记录治疗前后最佳矫正视力和中心视网膜厚度的变化.结果经3个月的随访,21例患者视力皆有不同程度的提高,初诊视力与术后4、8、12周最佳矫正视力相比,差异有统计学意义(t =9.170、8.508、8.530,P＜0.05);术前中央视网膜厚度与术后4、8、12周相比,差异有统计学意义(t =9.170、8.508、8.530,P＜0.05);中央视网膜厚度术后4周和术后8周及术后12周相比,差异无统计学意义(t=1.756、1.993,P ＞0.05).结论研究结果提示,PDT联合Ranibizumab玻璃体腔注射治疗视网膜大动脉瘤疗效显著,可以降低中央视网膜厚度,提高患者视力.
목적 평개광동력요법연합뢰주단항(Ranibizumab)파리체강주사치료시망막대동맥류적료효.방법 대2010년1월지2014년2월재해방군제사칠사의원안과취진적21례(21지안)경광동력요법(PDT)연합Ranibizumab파리체강주사치료시망막대동맥류(RAM)환자자료진행회고성분석.기중남성9례,녀성12례,년령56～80세,평균년령(61.5±10.6)세,균위초차취진혹시이전취진이학진,단시종미접수치료적시망막대동맥류환자.소유환자재광동력요법후72 h후지1주내행Ranibizumab파리체강주사(0.5 mg/0.05 ml),병재주사후4、8、12주수방,기록치료전후최가교정시력화중심시망막후도적변화.결과 경3개월적수방,21례환자시력개유불동정도적제고,초진시력여술후4、8、12주최가교정시력상비,차이유통계학의의(t =9.170、8.508、8.530,P＜0.05);술전중앙시망막후도여술후4、8、12주상비,차이유통계학의의(t =9.170、8.508、8.530,P＜0.05);중앙시망막후도술후4주화술후8주급술후12주상비,차이무통계학의의(t=1.756、1.993,P ＞0.05).결론 연구결과제시,PDT연합Ranibizumab파리체강주사치료시망막대동맥류료효현저,가이강저중앙시망막후도,제고환자시력.
Objective To evaluate the preliminary results for patients treated with combined photodynamic therapy (PDT) with verteporfin and intravitreal Ranibizumab for retinal macroaneurysm.Methods A retrospective series of 21 cases (21 eyes) with retinal macroaneurysm.Patients were treated with PDT with verteporfin and 2mg (0.2ml) of intravitreal Ranibizumab,among of them 9 were male and 12 were female.The average age was of 61.5 years old.All of the patients were the first time diagnosed as the retinal macroaneurysm or previously diagnosed but never received treatment.All the patients accepted PDT first and had intravitreal Ranibizumab within 72 hours to 1 week.Best corrected visual acuity (BCVA) and central retinal thickness were recorded after the injection of 4,8 and 12 weeks,while observing the presence of complications.Results At the 3 months follow-up,21 patients all had improvement in visual acuity.The BCVA were significantly improved in the 4,8 and 12 weeks.The CRT was significantly decreased in the 4,8 and 12 weeks.When comparing the CRT in the 4,8 and 12 weeks,the results were significantly decreased.Conclusions The results of this study suggest that combined treatment of PDT with verteporfin and intravitreal Ranibizumab may be useful in treating retinal macroaneurysm,which can reduce the CRT and improve the BCVA.